Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions MDD
Phase PHASE2
Enrollment 100
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomized placebo controlled trial is to compare the antidepressant effect of a single oral dose of psilocybin 25 mg compared to 1 mg in 100 patients with cancer related major depressive disorder. The main question it aims to answer is: The primary objective of this study is to evaluate the efficacy of a single 25 mg oral dose of psilocybin for major depressive disorder (MDD) compared to an active placebo (psilocybin 1 mg) assessed as the difference between groups in changes in depressive symptoms, in the following Population: 20-80 (inclusive) years old, current depressive episode (according to Patient Health Questionnaire (PHQ-9) ≥10), \>1 month after cancer diagnosis, with at least 12 months of life expectancy, willingness to abstain from other psychotherapeutic or antidepressant treatments during the study (wash out time 5 half-lives).

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: psilocybin 25 mg sod — psilocybin 25 mg sod
  • Drug: psilocybin 1 mg sod — active placebo

Primary Outcomes

  • MADRS at day 42 (day 42)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-04-19
Completion: 2026-12
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Section for Affective Disorders; Northern Stockholm Psychiatry
Collaborators: Uppsala University Hospital, Region Örebro County, Vastra Gotaland Region, Karolinska Institutet
Principal Investigators:
  • Johan Lundberg, MD PhD (PRINCIPAL_INVESTIGATOR) - Norra Stockholms Psykiatri and Karolinska Institutet
Contact Information
Study Contact:
Johan Lundberg
0812340000
johan.lundberg@ki.se
Helena Werin Sjögren, MD
helena.werin.sjogren@vgregion.se
region Västra Götaland
Mikael Landén, MD PhD
region Västra Götaland
Interventions
  • Drug: psilocybin 25 mg sod — psilocybin 25 mg sod
  • Drug: psilocybin 1 mg sod — active placebo
Study Locations (4 sites)
region Västra Götaland, Gothenburg, Göteborg Sweden
Norra Stockholms Psykiatri, Stockholm, Stockholm County Sweden
Psykiatriska Kliniken, Akademiska Sjukhuset, Uppsala, Uppsala County Sweden
Örebro sjukhus, Örebro, Örebro County Sweden
Eligibility Criteria
Inclusion Criteria * signed informed consent via minavårdkontakter.se * Are 20 to 80 (inclusive) years old at the time of signed informed consent * Are able to read, speak, and understand Swedish * Are able and willing to adhere to study requirements, including attending all study visits, preparatory and follow-up sessions, and completing all study evaluations * Are able to swallow capsules * Women of childbearing potential (WOCBP) must agree to practice an effective means of birth control throughout the duration of exposure to the Investigational Product, from Screening through the Day 8. * A diagnosis of a malignant neoplasm with a diagnostic code from C00 to C97 according to the International Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) * ≥1 month after cancer diagnosis and ≥ 12 months of life expectancy at time of inclusion * physical functioning performance status 0-2 (World Health Organisation/Eastern Cooperative Oncology Group (WHO/ECOG)) * Meet ICD-10 criteria for a diagnosis of major depressive disorder and are currently experiencing a major depressive episode of at least a 30-day duration at the time of the Screening less than 1 year at time of Screening * Have moderate-severe depression symptoms at Screening, as defined by a Screening PHQ-9 total score ≥ 10. * Are willing to abstain from other psychotherapeutic or antidepressant treatments during the study period (180 days; wash out time 5 half-lives). Note, if antidepressant treatment becomes needed as determined by the study physician this will be supported by the study personnel. * Have an identified support person. * Agree to be driven/accompanied home (or to an otherwise safe destination) by the support person, or another responsible party, following dosing Exclusion Criteria * Individuals not eligible to be randomized in this protocol are those who meet any of the following criteria: * Last contact with health care due to cancer monitoring or treatment \>1 year ago. * Women who are pregnant, as indicated by a positive urine pregnancy test at Screening or Baseline. Women who intend to become pregnant during the study or who are currently nursing. * Unwilling or unable to discontinue formal psychotherapy * Ongoing antidepressant drug treatment. No interruption of ongoing antidepressant treatment will be done on the initiation of the study personnel. Patients will be encouraged to discuss any interruption with their responsible clinical physician. * Have previously during the current episode received the following non-medication treatments: deep brain stimulation (DBS); vagus nerve stimulation (VNS) * Currently receiving electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) * Unable or unwilling to discontinue any current medications that are known uridine diphosphate (UDP) or glucuronosyltransferase (UGT) enzyme modulators (eg valproate) Note: Any prohibited agents must have been stopped at least 5x the elimination half-life of the specific drug plus one week at the time of Baseline. See Appendix A for a full list of prohibited medications. * Report psychedelic substances use ever o Note: Psychedelic substances include psilocybin, Lysergic acid diethylamide (LSD), mescaline (and natural products containing mescaline including peyote and San Pedro cactus), N,N-Dimethyltryptamine (DMT), natural products containing DMT including ayahuasca and 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), ibogaine, 3,4-methylenedioxy- methamphetamine (MDMA) or other psychedelics. * Cancer at time of inclusion involving the Central Nervous System (CNS) (as determined by a clinical examination or Magnetic Resonance Imaging (MRI)) * Cancer treatment/follow up regime determined to be incompatible with the CAPSI protocol (eg due to time lines, interaction between cancer treatment and psilocybin 25 mg or 1 mg exposure). * Have any of the following cardiovascular conditions: * congenital long QT syndrome (prior diagnosis), * any of the following if disabling physical exercise similar to walking two stairs without pause: coronary artery disease, cardiac hypertrophy, cardiac ischemia, congestive heart failure * a clinically significant Screening Electro Cardio-Graphy (ECG) abnormality (e.g., atrial fibrillation); * artificial heart valve; or * any other significant current or history of cardiovascular condition, based on the clinical judgment of study physician, that would make a participant unsuitable for the study * At Screening or Baseline have elevated blood pressure as defined as: a. Screening blood pressure Systolic Blood Pressure \>150 mmHg or Diastolic Blood Pressure \> 95 mmHg on three separate readings; or o Baseline blood pressure SBP \>160 mmHg or DBP \> 100 mmHg on three separate readings * Have a history of stroke or Transient Ischemic Attack (TIA) * Have moderate to severe hepatic impairment, as indexed by a Child-Pugh score ≥ 7 * Have uncontrolled epilepsy * Have insulin-dependent diabetes * Note: Participants who are taking oral hypoglycemic agent and have a history of hypoglycemia requiring medical intervention will be excluded * Are unable or unwilling to adhere to the following medication requirements: * Agree to suspend sildenafil (Viagra®), tadalafil, or similar medications at least 72 hours prior to dosing * Have a positive urine drug test including Amphetamines, Barbiturates, Buprenorphine, Benzodiazepines, Cocaine, Cannabis, Methamphetamine, MDMA, Methadone, Opiates (Morphine, Oxycodone), Phencyclidine (PCP), and Tetrahydrocannabinol (THC). Exceptions are made for prescribed Benzodiazepines (stable dose for sleep or anxiety). o Note: Benzodiazepine medications for sleep and non-benzodiazepine sleeping medications will be allowed to continue through the study period for participants who have been on a stable dose of such a medicine for at least 6 weeks prior to Screening, as determined during review of concomitant medications Note: Participants using cannabis, including legal cannabis, for any purposes will be excluded Note: Participants who are taking prescription maintenance methadone or buprenorphine naloxone will be excluded Note: Prescription opiates must have been stopped at least 5x the elimination half- life of the specific drug at the time of inclusion, as confirmed with a negative urine drug screen. * Nicotine dependence that would disallow an individual to be nicotine free for the 7-10 hours during the dosing period * Meet International Classification of Diseases version 10 (ICD-10) criteria for schizophrenia spectrum or other psychotic disorders, including MDD with psychotic features (except substance/medication-induced or due to another medical condition), or Bipolar I Disorder, Bipolar II Disorder. Note: Participants with any lifetime diagnosis of schizophrenia spectrum or other psychotic disorders will be excluded * Meet ICD-10 criteria for antisocial personality disorder * Meet ICD-10 criteria for a moderate or severe alcohol or drug use disorder (excluding caffeine) Note: Participants with a diagnosis of alcohol or drug use disorder within the past 12 months will be excluded * Have the presence of any psychiatric condition or symptom judged by the PI (or designee) to be a more significant clinical problem than MDD for the participant. * Have a first-degree relative with schizophrenia spectrum or other psychotic disorders (except substance/medication-induced or due to another medical condition). * Have a psychiatric condition judged to be incompatible with establishment of rapport with the Facilitators or safe exposure to psilocybin * Report the following suicidal ideation or suicidal thoughts defined as * Have a score of ≥ 5 on Item 10 (suicidal thoughts) on MADRS at Screening or Baseline; or * Have any suicidal ideation or thoughts, in the opinion of the study physician or PI, that presents a serious risk of suicidal or self-injurious behavior at any time prior to randomization * Ha
Conditions Parkinson Disease, Depression, PARKINSON...
Phase PHASE2
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the use of an oral multi-strain probiotic in the treatment of depression in individuals with Parkinson's Disease. Participants will be randomized to either a 12-week multi-strain probiotic treatment or placebo intervention.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Probiotic — Oral probiotic delivered in powdered form.
  • Dietary Supplement: Placebo — Oral placebo delivered in powdered form.

Primary Outcomes

  • Inventory of Depressive Symptomatology - Clinician-Rated (IDS-C) (13 weeks)
  • Beck Depression Inventory, 2nd Edition (BDI-II) (13 weeks)
  • Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR) (13 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-01-20
Completion: 2027-12-31
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of British Columbia
Contact Information
Study Contact:
Matthew Leung, BSc
604-827-1905
Matthew.Leung@ubc.ca
Annie Kuan
604-827-0576
annie.kuan@ubc.ca
Annie Kuan
604-827-0576
annie.kuan@ubc.ca
Pacific Parkinson's Research Centre
Interventions
  • Dietary Supplement: Probiotic — Oral probiotic delivered in powdered form.
  • Dietary Supplement: Placebo — Oral placebo delivered in powdered form.
Study Locations (1 sites)
Pacific Parkinson's Research Centre, Vancouver, British Columbia V6T2B5 Canada
Eligibility Criteria
Inclusion Criteria: 1. Confirmed diagnosis of Parkinson's disease based on UK Brain Bank criteria 2. Between the ages of 40-80 years 3. Mild to Moderate PD (Hoehn and Yahr stage between 1-3 in the "ON" state) 4. Mild to moderate depression (BDI-II score of 14-28 in the "ON" state) 5. Women of childbearing potential must agree to use a medically approved method of birth control (e.g., hormonal contraceptives, intrauterine devices, vasectomy/tubal litigation, barrier methods and double barrier method) and must have negative pregnancy test results at screening and baseline 6. Willingness to maintain current physical activity levels during study period 7. English proficiency Exclusion Criteria: 1. Atypical Parkinsonism 2. Active suicidality 3. Active psychosis 4. Cognitive score (MoCA) of \< 21 in the "ON" state 5. Severe depression (BDI-II score \> 28 in the "ON" state) 6. Probiotic, Saccharomyces boulardii and/or antibiotic use in the past 3 months (yogurt, kefir, and other probiotic-containing foods are allowed) 7. The use of natural health products that affect depression (e.g., St. John's Wort, passion flower, gaba, 5-htp, kava, bacopa, efa's) 8. Change in the schedule of concurrent psychotherapy or brain stimulation for the treatment of mood or anxiety disorders in the last 4 weeks 9. Change in antidepressant or anxiolytic medication (including benzodiazepines) within the last 4 weeks 10. Change in Parkinson's medication within the last 2 weeks 11. Neurological disease other than PD, including Alzheimer's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, a brain tumour, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma 12. A significant immune-compromised condition due to either a health condition or use of an immune suppressant (e.g., AIDS, lymphoma, chemotherapy treatment, patients undergoing long-term systemic corticosteroid or immunosuppressant treatment) 13. A known bleeding disorder 14. Current illness (e.g., a cold or flu-like symptoms) and infections (e.g., hepatitis, HIV, gastroenteritis, fungal, or parasitic infections) 15. Allergy to corn starch or corn 16. Concurrent treatment for Parkinson's disease with Duodopa 17. Change in Deep Brain Stimulation (DBS) stimulation parameters in the last 4 weeks 18. New onset of significant psychiatric symptoms following DBS procedure that are considered likely related 19. Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial 20. Unstable medical conditions or serious disease/conditions (e.g., cancer undergoing active treatment, poorly controlled diabetes) 21. Drug and/or substance abuse 22. The patient, in the opinion of the Investigator, is unable to adhere to the requirements of the study. This includes any patient who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a significant language barrier or cognitive impairment

Sleep Promotion Program Primary Care

NCT06240325
Recruiting
Conditions Sleep, Sleep Disturbance, Insufficient S...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

Investigators developed a brief, scalable, behavioral Sleep Promotion Program (SPP) for adolescents with short sleep duration and sleep-wake irregularity, which relies on two individual sessions and smart phone technology to deliver evidence-based strategies. This R34 will test the feasibility and initial effectiveness of the SPP program and provider training via pilot randomized controlled trial (RCT, n=50) comparing SPP to Sleep Psychoeducation, a brief session on healthy sleep habits. Participants will be adolescents (12-18 years) with short sleep duration, sleep-wake irregularity, and depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: SPP — SPP prioritizes increasing sleep duration and regularizing sleep-wake timing. The provider and youth review the youth's sleep pattern, based on sleep diary data collected before and during the program and actigraphy data collected at baseline. They discuss benefits to the current sleep pattern, reasons for changing sleep, and they create an action plan. Psychoeducation about healthy sleep is offered via a handout developed by our group. Youth and provider jointly select SPP strategies relevant to the contributors to poor sleep for each youth (e.g., time management, limiting weekend oversleep). In the second session they review progress and adjust the plan. Parents participate for part of each session to learn about their child's sleep and to discuss ways they can support their child to make the planned changes.
  • Behavioral: Sleep Psychoeducation — Using the pamphlet also used in SPP, SPE will present sleep hygiene practices commonly included in sleep education programs and endorsed by national health organizations.

Primary Outcomes

  • Feasibility of Intervention Measure (Post-Intervention (~8 weeks))
  • Acceptability of Intervention Measure (Post-Intervention (~8 weeks))
  • Intervention Appropriateness Measure (Post-Intervention (~8 weeks))
  • Clinical Global Impressions Scale - Improvement (Post-Intervention (~8 weeks))
  • Patient Health Questionnaire - 9 - M (Change Screening to Post-Intervention (~10 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-13
Completion: 2026-11-30
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pittsburgh
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Jessica C Levenson (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Jessica C Levenson
412-647-7937
levensonjc@upmc.edu
Paige DeGennaro
412-246-5974
degennaropl@upmc.edu
Jessica C Levenson
4126477937
levensonjc@upmc.edu
University of Pittsburgh
Interventions
  • Behavioral: SPP — SPP prioritizes increasing sleep duration and regularizing sleep-wake timing. The provider and youth review the youth's sleep pattern, based on sleep diary data collected before and during the program and actigraphy data collected at baseline. They discuss benefits to the current sleep pattern, reasons for changing sleep, and they create an action plan. Psychoeducation about healthy sleep is offered via a handout developed by our group. Youth and provider jointly select SPP strategies relevant to the contributors to poor sleep for each youth (e.g., time management, limiting weekend oversleep). In the second session they review progress and adjust the plan. Parents participate for part of each session to learn about their child's sleep and to discuss ways they can support their child to make the planned changes.
  • Behavioral: Sleep Psychoeducation — Using the pamphlet also used in SPP, SPE will present sleep hygiene practices commonly included in sleep education programs and endorsed by national health organizations.
Study Locations (1 sites)
University of Pittsburgh, Pittsburgh, Pennsylvania 15217 United States
Eligibility Criteria
Inclusion Criteria: Youth: * Able and willing to provide informed assent (with consent from parent/guardian) * Ages 12-18 * Currently a patient at Kids Plus Pediatrics * Currently depressed * Report short sleep duration (\<7 hours on school nights) and/or weekday-weekend sleep timing difference of \>=2 hours Parents: Parents must be age 18 or older and the parent/guardian of an enrolled youth participant and must have at least 10 hours face-to-face interaction with the youth participant per week. Exclusion Criteria: Youth: * Significant or unstable medical conditions * Diagnosis of sleep apnea, narcolepsy, restless leg syndrome, nightmare disorder, or periodic limb movement disorder * Diagnosis of PTSD, bipolar disorder, a psychotic disorder, or substance use disorder * Currently engaged in cognitive and/or behavioral therapy that aims to improve sleep * Changes in medications in the month prior to screening * Active suicidality requiring immediate treatment * Unable or unwilling to comply with study procedures * Have any physical or mental condition that would preclude study participation. Parents will be excluded if they: * Express active suicidality that requires immediate treatment; * Have any physical or mental condition that would preclude study participation; OR * Are unable or unwilling to comply with study procedures.
Conditions Depressive Disorder, Major
Phase PHASE2, PHASE3
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

This is a phase 2 and 3 adaptive design study for Mitizodone Phosphate,to find out an optimal dose in phase 2 period and confirm the result an efficacy and safety in phase 3 period.Dose-finding will be done after 8 weeks of double-blinded treatment in phase 2 period and will be assessed by both efficacy and safety from 3 dose groups of Mitizodone Phosphate.The dose be found in phase 2 period will be evaluated on efficacy and safety when compared with placebo in phase 3 period with a duration of 8 weeks treatment.The target subjects are patients with MDD.

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Mitizodone Phosphate tablets — Mitizodone Phosphate tablets will be administered with food.
  • Drug: Placebo-matching tablets — Placebo will be administered with food.

Primary Outcomes

  • Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at week 8 (baseline and week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2021-12-14
Completion: 2027-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sunshine Lake Pharma Co., Ltd.
Contact Information
Study Contact:
gang wang, Ph.D
86-010-58303236
gangwangdoc@gmail.com
Li Xue
+8676985315888
lixuelc@hec.cn
Sunshine Lake Pharma Co., Ltd.
Interventions
  • Drug: Mitizodone Phosphate tablets — Mitizodone Phosphate tablets will be administered with food.
  • Drug: Placebo-matching tablets — Placebo will be administered with food.
Study Locations (1 sites)
Sunshine Lake Pharma Co., Ltd., Dongguan, Guangdong 523871 China
Eligibility Criteria
Inclusion Criteria: * 1.a Man or a woman with major depressive disorder(MDD) as the primary diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria (classification code 296.22、296.23、296.32、296.33) * 2.Has a Montgomery Åsberg Depression Rating Scale (MADRS) total score of 26 or greater at Screening and Baseline Visits. * 3.Has a Clinical Global Impression - Severity of Illness (CGI-S) score of 4 or greater at Screening and Baseline Visits. Exclusion Criteria: * 1.has major depressive disorder with psychotic features according to the DSM-5. * 2.Current or history of: bipolar disorder、schizophrenia、anixety disorder、insomnia、any substance abuse or dependence and other psychiatry disorder as defined in the DSM-5. * 3.Current or history of a clinically significant neurological disorder (including epilepsy、Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease). * 4\. has Serious body disease such as neurological disorders、cardiacvascular disorders、hepatic disorders、 renal disorders, blood system disorders and endocrine disorders. * 5\. Current or history of cancer( except basal cell of the skin and preinvasive carcinoma of cervix uteri). * 6\. Current or history of angle-closure glaucoma. * 7\. has made a suicide behavior in the previous 1 year ,or has a score greater than or equal to 4 on item 10 (suicidal thoughts) of MADRS . * 8.has taken fluoxetine within 4 weeks prior to initial dosing. * 9\. has taken other antidepressive medications or antipsychotic medications within 2 weeks prior to initial dosing. * 10.has psychotherap at Screening and/or Baseline Visits. * 11.has had physiotherapy within 3 months prior to initial dosing. * 12.Has an alanine aminotransferase, aspartate aminotransferase or total bilirubin level greater than 1.5 times the upper limits of normal. * 13.Has an alanine aminotransferase, aspartate aminotransferase level greater than 2 times the upper limits of normal;or total bilirubin, direct bilirubin,creatinine level greater than 1.5 times the upper limits of normal;or a thyroid stimulating hormone value outside the normal range. * 14.Has an abnormal electrocardiogram confirmed as clinically significant by the investigator. * 15.Has a history of severe allergies.
Conditions Quality of Life, PTSD, Depression Not Ot...
Phase NA
Enrollment 348
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

Pediatric traumatic injury (PTI) is a public health priority, with more than 125,000 children experiencing injuries that require hospitalization each year. These children, and their caregivers, are affected in many ways that may affect quality of life, emotional and behavioral health, physical recovery, family roles and routines, and academic functioning; yet US trauma centers do not adequately address these outcomes and a scalable national model of care for these families is needed. This proposal builds on prior research from the investigative team to test a technology-assisted, stepped care behavioral health intervention for children (\&lt;12 years) and their caregivers after PTI, CAARE (Caregivers' Aid to Accelerate Recovery after pediatric Emergencies), via a hybrid type I effectiveness-implementation trial with 348 families randomly assigned to CAARE (n=174) vs. guideline-adherent enhanced usual care (EUC) (n=174).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Caregivers' Aid to Accelerate Recovery after pediatric Emergencies (CAARE) — CAARE is a technology-enhanced stepped model of care that is designed to deliver education at the bedside to caregivers of children under age 12 years hospitalized for pediatric injury about mental health recovery after pediatric injury as well as risk assessment and brief intervention for high-risk patients (Step 1), foster symptom self-monitoring and reinforcement of coping skills via mHealth tools (Step 2), screen for caregivers' and children's PTSD and depression 30 days post-injury (Step 3), and provide a referral and warm hand-off to mental health services if needed (Step 4).

Primary Outcomes

  • Change in scores in child self-report and caregiver proxy-report of child Quality of Life (QOL) (From enrollment (baseline) to 3-month, to 6-month, until end of treatment at 12-month)
  • Change in scores in caregiver self-report of PTSD (From 3-month, to 6-month, until end of treatment at 12-month)
  • Change in scores in caregiver self-report of caregiver depression (From 3-month, to 6-month, until end of treatment at 12-month)
  • Change of child externalizing problems from 3 month to 12 month (From 3-month, to 6-month, until end of treatment at 12-month)
  • Change in scores in child self-report and caregiver proxy-report of child PTSD (From 3-month, to 6-month, until end of treatment at 12-month)
  • Change in scores in child self-report (ages 6-11) of child depression (From 3-month, to 6-month, until end of treatment at 12-month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-28
Completion: 2028-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 348 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of South Carolina
Collaborators: National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Principal Investigators:
  • Leigh Ridings, Ph.D. (PRINCIPAL_INVESTIGATOR) - Medical University of South Carolina
Contact Information
Study Contact:
Leigh Ridings
(843) 792-5146
ridingle@musc.edu
Ebonie Powell
powelebo@musc.edu
Ryan Spurrier
323.361.2322
rspurrier@chla.usc.edu
Children's Hospital Los Angeles
Interventions
  • Behavioral: Caregivers' Aid to Accelerate Recovery after pediatric Emergencies (CAARE) — CAARE is a technology-enhanced stepped model of care that is designed to deliver education at the bedside to caregivers of children under age 12 years hospitalized for pediatric injury about mental health recovery after pediatric injury as well as risk assessment and brief intervention for high-risk patients (Step 1), foster symptom self-monitoring and reinforcement of coping skills via mHealth tools (Step 2), screen for caregivers' and children's PTSD and depression 30 days post-injury (Step 3), and provide a referral and warm hand-off to mental health services if needed (Step 4).
Study Locations (4 sites)
Children's Hospital Los Angeles, Los Angeles, California 90027 United States
Kentucky Children's Hospital, Lexington, Kentucky 40536 United States
C.S. Mott Children's Hospital, Ann Arbor, Michigan 48109 United States
Children's Memorial Hermann Hospital, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Caregivers (≥18 years old) of children hospitalized with pediatric injury * Children hospitalized with pediatric injury \&lt;12 years old * Screen positive on the ASC-Kids (aged 6-11 years) or PDI Caregiver measure of acute distress. Exclusion Criteria: * A caregiver whose primary language is not English or Spanish * A cognitive challenge (caregiver or child) that would impair ability to consent * Presence of a self-afflicted injury * Presence of injuries resulting from caregiver abuse or neglect (these patients will follow an alternative treatment path).
Conditions Perimenopause, Perimenopausal Depression...
Phase Not Applicable
Enrollment 110
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to investigate the accuracy of the device in characterizing perimenopausal and menopausal symptoms including vasomotor symptoms, anxiety, sleep quality compared to self-reported symptoms via an app. The main question it aims to answer is: What is the accuracy of the developed algorithm from the investigational device compared to daily self-report via an app in characterizing perimenopausal symptoms? Participants will be asked to wear IndentifyHer's wearable non-invasive sensor and complete a daily electronic diary and questionnaires on stress, anxiety, and sleep.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Primary Outcomes

  • The accuracy of the developed algorithm from the investigational device compared to daily self-report questionnaire via an app in characterizing Vasomotor symptoms. (Day 0 to 14)
  • The accuracy of the developed algorithm from the investigational device compared to daily self-report questionnaire via an app in characterizing anxiety (Day 0 to 14)
  • The accuracy of the developed algorithm from the investigational device compared to daily self-report questionnaire via an app in characterizing sleep quality (Day 0 to 14)
  • The accuracy of the developed algorithm from the investigational device compared to daily self-report questionnaire via an app in characterizing perimenopausal symptoms considering confounders (Day 0 to 14)
  • The accuracy of the developed algorithm from the investigational device compared to daily self-report questionnaire via an app in characterizing perimenopausal symptoms considering confounders (Day 0 to 14)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-07-04
Completion: 2025-10
Eligibility
Age: 35 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 110 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: IdentifyHer Limited
Collaborators: KGK Science Inc.
Principal Investigators:
  • David Crowley, MD (PRINCIPAL_INVESTIGATOR) - KGK Science Inc.
Contact Information
Study Contact:
Marc Moulin, PhD
+12267819094;ext=300
mmoulin@kgkscience.com
Marc Moulin, PhD
+12267819094;ext=300
mmoulin@kgkscience.com
KGK Science Inc.
David Crowley, MD
dcrowley@kgkscience.com
KGK Science Inc.
Interventions
N/A
Study Locations (1 sites)
KGK Science Inc., London, Ontario N6B3L1 Canada
Eligibility Criteria
Inclusion Criteria: 1. Females between 35-55 years of age, inclusive 2. Self-reported perimenopausal women experiencing hot flushes or night sweats 3. Individuals of child-bearing potential must confirm they are not pregnant, do not plan to become pregnant, and agree to use a medically approved method of birth control for the duration of the study. Acceptable methods of birth control include: * Double-barrier method * Intrauterine devices * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) * Vasectomy of partner at least 6 months prior to screening * Abstinence 4. Agrees to maintain current lifestyle as much as possible throughout the study, including diet, exercise, supplements/medications, and sleep 5. Provided voluntary and informed consent to participate in the study 6. Generally healthy as determined by medical history with no unstable diagnosed medical conditions Exclusion Criteria: 1. Allergy or sensitivity to adhesive used for wearing the investigational device 2. Self-reported use of a pacemaker 3. Self-reported unstable diagnosed anxiety disorder 4. Self-reported sleep disorder requiring medical treatment 5. Self-reported skin conditions or sensitive skin around the area of application 6. Self-reported surgery in the past three months or individuals who have planned surgery during the course of the study 7. Alcohol intake average of ˃1 standard drink per day 8. Alcohol or drug abuse within the last 12 months that has required treatment 9. Current use of prescribed and/or over-the-counter (OTC) medications/supplements that may impact data recorded by the investigational device (see Section 7.3) 10. Participation in other clinical research studies 30 days prior to screening 11. Individuals who are unable to give informed consent 12. Any other condition or lifestyle factor, that may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
Conditions Down Syndrome
Phase NA
Enrollment 62
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the efficacy of transcranial direct current stimulation (tDCS) for depression with catatonia in individuals with Down syndrome (DS). 62 patients will be randomized to receive 15 sessions of active or sham tDCS. The primary objective is to measure changes in depressive/catatonic symptoms using the Bush-Francis Catatonia Rating Scale (BFCRS). Secondary objectives include safety, cognitive effects, EEG correlates, and biological markers (cortisol, BDNF, cytokines). The study aims to provide a non-pharmacological therapeutic alternative for this population

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: Transcranial stimulation — A randomized, 2-arm, sham-controlled study, patients with Down syndrome presenting with major depressive episode (DSM5) with catatonic features will be randomly allocated to receive 15 sessions of either active (20 min, 2mA, ramp up/down 30 sec) or sham tDCS (20 min, ramp up/down 30 sec at the beginning and at the end of each stimulation session), thrice daily. Each stimulation session will be spaced at least two hours apart. The anode will be placed over the left DLPFC, the cathode over the right DLPFC using the Beam F3 algorithm in order to individualize target location based on head circumference, tragus to tragus and inion to nasion distances.

Primary Outcomes

  • Acute changes on depressive / catatonic symptoms between D0 and D5 measured with the Bush-Francis Catatonia Rating Scale (BFCRS) (27 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-12
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 62 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hôpital le Vinatier
Principal Investigators:
  • CAROLINE C DEMILY, MD PhD HDR (PRINCIPAL_INVESTIGATOR) - HOPITAL VINATIER
Contact Information
Study Contact:
JEROME J BRUNELIN, PhD, HDR)
00334 37 91 54 95
jerome.brunelin@ch-le-vinatier.fr
VERONIQUE V VIAL
0033437915522
veronique.vial@ch-le-vinatier.fr
DEMILY MD CAROLINE, PH
0033437915163
caroline.demily@ch-le-vinatier.fr
Hopital Vinatier
Interventions
  • Device: Transcranial stimulation — A randomized, 2-arm, sham-controlled study, patients with Down syndrome presenting with major depressive episode (DSM5) with catatonic features will be randomly allocated to receive 15 sessions of either active (20 min, 2mA, ramp up/down 30 sec) or sham tDCS (20 min, ramp up/down 30 sec at the beginning and at the end of each stimulation session), thrice daily. Each stimulation session will be spaced at least two hours apart. The anode will be placed over the left DLPFC, the cathode over the right DLPFC using the Beam F3 algorithm in order to individualize target location based on head circumference, tragus to tragus and inion to nasion distances.
Study Locations (1 sites)
Hopital Vinatier, Lyon, Auvergne-Rhône-Alpes 69678 France
Eligibility Criteria
Inclusion Criteria: * Patient with Down syndrome * Age \> 18 * Diagnosis of Major Depressive Disorder MDD with catatonic symptoms according to the DSM-5 criteria * Informed consent signed by the patient, by the patient under curatorship, or by the legal representative in the case of a patient under guardianship. * Person affiliated to the French social security system or equivalent Exclusion Criteria: * Pregnancy (checked with a pregnancy test) * Contraindication for tDCS(i.e., cochlear implant) * Refusal of the patients or their legal representatives * Other persons protected under the CSP (judicial safeguard, family habilitation)
Conditions Older Adults (50-90 Years), Mental Healt...
Phase NA
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

This PN-RCT replicates and evaluates an 8-week warm calling treatment (i.e. caring contacts) delivered to older adults receiving home and community-based services (HCBS; classified as "homebound") in 20-30 minute call "dosages", across 3 conditions, while adding in implementation science measures at multiple levels. Conditions include 2 treatment (i.e. treatment provided by helpers trained in a standardized and manualized Belongingness and Empathy training grounded in narrative reminiscence and the befriending literature (BE condition), and treatment provided by helpers trained in BE + a standardized, manualized, and evidence based suicide intervention training, the Aging Variant of LivingWorks ASIST (BE + ASIST condition), and 1 control (no treatment during the trial; opportunity to receive treatment after the 8 weeks). At the conclusion of treatment, acceptability, appropriateness, feasibility, useability, and sustainability of the program will be evaluated by interventionists, senior center leadership, and regional leadership.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: Standardized and manualized warm calls from providers trained in the BE training — Weekly call dosages averaging 20-30 minutes each, for 8 weeks duration; with a 6 month follow up.
  • Behavioral: Standardized and manualized warm calls from providers trained in the BE training + ASIST training — Weekly call dosages averaging 20-30 minutes each, for 8 weeks duration; with a 6 month follow up.

Primary Outcomes

  • Social Provisions Scale (SPS-5) (Baseline; 2 weeks, 4 weeks, 6 weeks, 8 weeks; 6 month follow up)
  • University of California, Los Angeles Loneliness Scale (Baseline; 2 weeks, 4 weeks, 6 weeks, 8 weeks; 6 month follow up)
  • Patient Health Questionnaire - PHQ-9 (Baseline; 2 weeks, 4 weeks, 6 weeks, 8 weeks; 6 month follow up)
  • Short Form Health Survey (SF-12) (Baseline; 2 weeks, 4 weeks, 6 weeks, 8 weeks; 6 month follow up)
  • Interpersonal Needs Questionnaire (INQ-15) (Baseline; 2 weeks, 4 weeks, 6 weeks, 8 weeks; 6 month follow up)
  • Implementation Science Sustainability Survey Measures: AIM (Baseline; 2 weeks, 4 weeks, 6 weeks, 8 weeks; 6 month follow up)
  • Implementation Science Sustainability Survey Measures: IAM (Baseline; 2 weeks, 4 weeks, 6 weeks, 8 weeks; 6 month follow up)
  • Implementation Science Sustainability Survey Measures: FIM (Baseline; 2 weeks, 4 weeks, 6 weeks, 8 weeks; 6 month follow up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-05
Completion: 2030-08-30
Eligibility
Age: 55 Years and older
Sex: ALL
Volunteers: true
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Florida
Collaborators: University of Louisiana at Lafayette, Virginia Polytechnic Institute and State University, Georgia State University
Contact Information
Study Contact:
Laura R Shannonhouse, PhD
352-273-4332
lshannonhouse@coe.ufl.edu
Interventions
  • Behavioral: Standardized and manualized warm calls from providers trained in the BE training — Weekly call dosages averaging 20-30 minutes each, for 8 weeks duration; with a 6 month follow up.
  • Behavioral: Standardized and manualized warm calls from providers trained in the BE training + ASIST training — Weekly call dosages averaging 20-30 minutes each, for 8 weeks duration; with a 6 month follow up.
Study Locations (1 sites)
University of Florida, Gainesville, Florida 32611 United States
Eligibility Criteria
In order to be eligible as a participant in this study, an individual must meet all of the following criteria: 1. Provision of verbal informed consent 2. Classify as an Older Adult (65+) 3. Stated willingness and ability to comply with all study procedures 4. Receive home and community-based services (HCBS) through the Aging Services Network (i.e. HDM (home delivered meals services), CM (congregate meals), etc.) 5. Be affiliated with the triple As and aging entities we have partnered with In order to be eligible to be a trained provider in this study, an individual must meet all of the following criteria: 1. Provision of written informed consent 2. State willingness to comply with all study procedures 3. Be a staff or volunteer within the ASN (Aging Services Network), specifically within the triple As and aging entities we have partnered with 4. Meet Wymann and colleagues (2008) criteria for being a "natural helpers"42 (i.e. be warm, empathic, and having ongoing interaction with participants through one's job role) 5. Be recommended by the aging entity leadership as meeting these qualifications In order to be eligible to be a leadership personnel in this study, an individual must meet all of the following criteria: 1. Provision of written informed consent 2. State willingness to comply with all study procedures 3. Be a in a leadership position within the aging entity or triple A in which we partnered, and have worked with the study team in helping implement the 8 week program Exclusion criteria for Participants: 1. Had a dementia diagnosis, or another form of cognitive impairment, and/or hearing impairment that would preclude phone conversation. 2. Participation in another warm calling behavioral treatment or intervention study simultaneously occurring Exclusion criteria for trained natural helpers: 1. Does not have ongoing interactions with potential old adult participants (i.e. is a part of an optimized nutrition service provider in which they do not serve the same older adults consistently over time) 2. Participation in another warm calling behavioral treatment or intervention study simultaneously occurring Exclusion criteria for aging leaders: 1. Has not worked with the study team directly in implementing the 8-week treatment 2. Is not familiar with the implementation of the program
Conditions Apathy, Stroke, Stroke Sequelae, Stroke/...
Phase PHASE1, PHASE2
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

Apathy is a common set of symptoms seen in many people following a stroke. Apathy occurs when a person has lost motivation, becomes withdrawn, and stops doing things that used to be important to them. Apathy has a large negative impact on a person's quality of life, and can also have a large impact the people who take care of them. There are currently no FDA-approved treatments to help with apathy, and other services like therapy may be difficult to access for people who have had a stroke. To address this problem, investigators are conducting a study to find out if a form of treatment called repetitive transcranial magnetic stimulation (rTMS) can be safe and helpful for people struggling with apathy after a stroke. This study will apply a new form of rTMS which can be delivered quickly to a part of the brain called the medial prefrontal cortex (mPFC). This study will help establish whether this treatment is safe, comfortable, and effective for people with apathy after a stroke, and will help researchers develop new forms of treatment.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active) — Active treatment will consist of high-dose iTBS-rTMS to left dmPFC delivered in runs of 600 pulses at an intensity of 120% resting motor threshold (rMT). iTBS triplets at 50 Hz will be delivered for 2 seconds, repeated every 10 seconds for a total of 190 seconds. Each session will be separated by at least 10-15 minutes and a total of 12 sessions will be given on each treatment day (3-4 hours per study day). A total of 43,200 pulses will be delivered over the entire six days of treatment.
  • Device: MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Sham) — For the sham stimulation group, a focal electric sham will be used which is indistinguishable from active TMS including a pretreatment individualized sham titration, sham outputs noises synchronized to pulse delivery, and an individualized level of sham stimulation throughout the treatment. Technicians administering active vs sham TMS will be masked by using a random code generated by the statistician that will indicate whether to use the active or sham side of the coil. Treatments will appear identical to the technician regardless of whether active or sham TMS is administered.
  • Other: Brainsight Neuronavigation System — A brainsight neuronavigation system will be used during TMS treatments to target treatment location using individual MRI data

Primary Outcomes

  • Change in apathy symptoms, as measured by the Lille Apathy Rating Scale (LARS) compared to baseline (Pre-treatment, immediately post-treatment, and at one month post-treatment follow-up)
  • Change in apathy symptoms as measured by the Apathy Evaluation Scale (AES) - Self and Informant Versions (Pre-treatment, immediately post-treatment, and weekly for four weeks post-treatment.)
  • Incidence of Treatment-Emergent Adverse Events and Side Effects as assessed by change in the Review of Systems Criteria compared to baseline (After each session of rTMS during each of six treatment days within two weeks)
  • Change From Baseline Cognition, as Measured by the Fluid Cognition Composite Score From the NIH Toolbox Cognition Battery compared to baseline (Pre-treatment, immediately post-treatmen)
  • Participant retention rate (calculated at the end of the study follow-up assessment period (one month post-treatment))
  • Patient perception of treatment acceptability as assessed by study-specific questionnaire (After each session of rTMS during each of three treatment days within one week, and at one month post-treatment follow-up)
  • Frontal Systems Behavior Scale (FrSBE)-Apathy scale (Pre-treatment, post-treatment and at 4 weeks post treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-08-08
Completion: 2027-06-30
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of South Carolina
Principal Investigators:
  • Parneet Grewal, PhD (PRINCIPAL_INVESTIGATOR) - Medical University of South Carolina
  • Lisa McTeague, PhD (PRINCIPAL_INVESTIGATOR) - Medical University of South Carolina
  • Kevin Caulfield, PhD (PRINCIPAL_INVESTIGATOR) - Medical University of South Carolina
Contact Information
Study Contact:
Parneet Grewal, MD
843-792-3020
grewalp@musc.edu
Lisa McTeague, PhD
843-792-8274
mcteague@musc.edu
Lisa McTeague, PhD
843-792-8274
mcteague@musc.edu
Medical University of South Carolina Brain Stimulation Lab
Interventions
  • Device: MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active) — Active treatment will consist of high-dose iTBS-rTMS to left dmPFC delivered in runs of 600 pulses at an intensity of 120% resting motor threshold (rMT). iTBS triplets at 50 Hz will be delivered for 2 seconds, repeated every 10 seconds for a total of 190 seconds. Each session will be separated by at least 10-15 minutes and a total of 12 sessions will be given on each treatment day (3-4 hours per study day). A total of 43,200 pulses will be delivered over the entire six days of treatment.
  • Device: MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Sham) — For the sham stimulation group, a focal electric sham will be used which is indistinguishable from active TMS including a pretreatment individualized sham titration, sham outputs noises synchronized to pulse delivery, and an individualized level of sham stimulation throughout the treatment. Technicians administering active vs sham TMS will be masked by using a random code generated by the statistician that will indicate whether to use the active or sham side of the coil. Treatments will appear identical to the technician regardless of whether active or sham TMS is administered.
  • Other: Brainsight Neuronavigation System — A brainsight neuronavigation system will be used during TMS treatments to target treatment location using individual MRI data
Study Locations (1 sites)
Medical University of South Carolina Brain Stimulation Lab, Charleston, South Carolina 29403 United States
Eligibility Criteria
Inclusion Criteria: * 40 years old or greater * Right- or left-hemisphere ischemic or hemorrhagic stroke with at least 6 months chronicity * Symptomatic apathy as confirmed by (A) total score on the Apathy Evaluation Scale by the participant or the caregiver/co-participant (AES) of ≥39 * Ability to participate in psychometric testing and cognitive tasks * Intact cortex at the TMS target site as confirmed by pre-treatment MRI * Ability to have a co-participant/caregiver who meets the criteria as detailed below. Exclusion Criteria: * Primary extra-axial hemorrhage (subdural or subarachnoid) without ischemic stroke or intraparenchymal hemorrhage * Concomitant neurological disorders affecting motor or cognitive function (e.g. dementia) * Moderate or severe global aphasia * Visual impairment precluding completion of cognitive tasks * Presence of contraindications to MRI or TMS including electrically, magnetically or mechanically activated metal or nonmetal implants such as cardiac pacemaker, intracerebral vascular clips or any other electrically sensitive support system; * Pregnancy (to be later confirmed by UPT in any premenopausal female participants) * History of a seizure disorder * Preexisting scalp lesion, wound, bone defect, or hemicraniectomy * Claustrophobia precluding ability to undergo an MRI * Active substance use disorder * Psychotic disorders * Bipolar 1 Disorder * Acute suicidality as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)30 or suicide attempt in the previous year For CO-PARTICIPANT/CAREGIVER: Inclusion Criteria: * Age 18 years or older * Is a reliable informant who has at least weekly contact with the participant and can speak to the participant's cognitive and everyday functioning. Exclusion Criteria: \- Unable to engage with study procedures in which Co-Participant input is needed.
Conditions Major Depressive Disorder, Treatment Res...
Phase NA
Enrollment 75
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

Repetitive transcranial magnetic stimulation (rTMS) has emerged as a promising intervention for treatment-resistant depression (TRD), yet substantial uncertainties persist regarding its efficacy as a maintenance treatment. This prospective study seeks to investigate the efficacy of maintenance rTMS in individuals with TRD who have previously responded to an acute course of rTMS. In the R61 phase of the study, we will recruit 75 participants across three study sites, the University of California San Diego, Weill Cornell Medicine, and Australian National University, into a double-blind, three-arm maintenance treatment trial. In this trial, participants will be randomized to receive either standard maintenance rTMS, clustered maintenance rTMS, or sham maintenance rTMS for a duration of 6 months. Our primary aim is to examine the efficacy of maintenance rTMS on sustaining connectivity between the dorsolateral prefrontal cortex (DLPFC) and subgenual cingulate cortex (SGC) measured through concurrent TMS and electroencephalography (TMS-EEG) at baseline and every six weeks throughout the 6-month treatment period. We will also assess changes in depressive symptom severity using clinical scales, including the Montgomery-Asberg Depression Rating Scale (MADRS) as a secondary outcome measure. It is hypothesized that stimulation with clustered maintenance rTMS will demonstrate superiority in sustaining DLPFC-SGC connectivity compared with standard maintenance rTMS and sham maintenance rTMS

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: Transcranial Magnetic Stimulation (TMS) - Standard maintenance rTMS: — In this approach, patients who were treated with rTMS five days per week during their acute episode receive less frequent treatments during a taper period (for example treatment three days per week followed by two sessions per week) with a gradual transition into a maintenance schedule. For example, the maintenance schedule might begin with a single weekly session for one or two months and then the intensity is reduced to one session every two weeks (and possibly then one session every three or four weeks).
  • Device: Transcranial Magnetic Stimulation (TMS) - Clustered maintenance rTMS: — Clustered maintenance rTMS typically involves around 4 TMS sessions applied over 2 days, at 1-month intervals. Our team initially developed this approach based upon preclinical TMS studies (for example (Maeda et al. 2000)) suggesting that rTMS treatment effects may accumulate when applied over multiple sessions in a shorter period of time (Maeda et al. 2000).
  • Device: Transcranial Magnetic Stimulation (TMS) -- Sham maintenance rTMS — Sham treatment will be administered as either standard or clustered maintenance rTMS for 6 months period using a sham coil. The intervention target will be located via a Brainsight TMS Navigator (Brainsight, Montreal, Canada). For safety reasons, the individual TMS intensity will be limited to 130% of the individual resting motor threshold.

Primary Outcomes

  • Aim: To evaluate the effects of two active rTMS maintenance treatments (i.e., standard and clustered) compared to sham maintenance rTMS on DLPFC-SGC connectivity. (6-months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-01
Completion: 2027-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Diego
Collaborators: National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
Interventional Psychiatry
858-657-6152
iptrials@health.ucsd.edu
Bianca Bacio
858-657-6152
bbacio@health.ucsd.edu
University of California, San Diego
Zafiris J Daskalakis, MD. Ph.D.
University of California, San Diego
Interventions
  • Device: Transcranial Magnetic Stimulation (TMS) - Standard maintenance rTMS: — In this approach, patients who were treated with rTMS five days per week during their acute episode receive less frequent treatments during a taper period (for example treatment three days per week followed by two sessions per week) with a gradual transition into a maintenance schedule. For example, the maintenance schedule might begin with a single weekly session for one or two months and then the intensity is reduced to one session every two weeks (and possibly then one session every three or four weeks).
  • Device: Transcranial Magnetic Stimulation (TMS) - Clustered maintenance rTMS: — Clustered maintenance rTMS typically involves around 4 TMS sessions applied over 2 days, at 1-month intervals. Our team initially developed this approach based upon preclinical TMS studies (for example (Maeda et al. 2000)) suggesting that rTMS treatment effects may accumulate when applied over multiple sessions in a shorter period of time (Maeda et al. 2000).
  • Device: Transcranial Magnetic Stimulation (TMS) -- Sham maintenance rTMS — Sham treatment will be administered as either standard or clustered maintenance rTMS for 6 months period using a sham coil. The intervention target will be located via a Brainsight TMS Navigator (Brainsight, Montreal, Canada). For safety reasons, the individual TMS intensity will be limited to 130% of the individual resting motor threshold.
Study Locations (3 sites)
University of California, San Diego, San Diego, California 92127 United States
Weill Cornell Medicine, New York, New York 10065 United States
Australian National University, Canberra, Australian Capital Territory 2601 Australia
Eligibility Criteria
Inclusion Criteria: 1. They met criteria for a DSM-5 diagnosis of a Major Depressive Episode (MDE) during the index episode of depression for which they have received an acute rTMS treatment course. 2. Meet criteria for either response or remission from their initial depressive illness. The MINI assessment timeline will be adjusted to allow scoring of illness symptoms prior to rTMS response. Response to acute course of treatment is defined as either a MADRS score of \<10, or a MADRS score of 10-19, plus evidence of having met response criteria on either the MADRS or another structured depression rating scale. The response is defined as a \>50% reduction in the total score from the start to the end of treatment. 3. Their initial rTMS treatment course must have consisted of at least 15 rTMS treatment sessions. 4. People between the ages of 18 and 80 at the time of screening. A written statement from the referring physician will be required to confirm that the participant demonstrates the capacity to consent. 5. Able to read, understand, and provide written, dated informed consent prior to screening. Proficiency in English sufficient to complete questionnaires / follow instructions during TMS-EEG assessments and iTBS interventions. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information. 6. In good general health, as evidenced by medical history. 7. Agreement to adhere to Lifestyle Considerations throughout study duration. 8. If a person of child-bearing potential is: must take a pregnancy test at the screening visit, with results confirmed as negative by study staff Exclusion Criteria: * 1\. Pregnancy 2. History of or current psychotic disorder or depression with psychotic features 3. Severe borderline personality disorder based on clinical assessment. 4. Diagnosis of Intellectual Disability or Autism Spectrum Disorder 5. Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal 6. Clinically significant suicidal ideation with plan 7. Any history of ECT (greater than 8 sessions) without a clinical meaningful response in the current episode. 8\. Recent (during the current depressive episode) or concurrent use of rapid-acting antidepressant agent (i.e., ketamine or a course of ECT) in the last 30 days 9. History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma 10. Untreated or insufficiently treated endocrine disorder. 11. Contraindications to receiving rTMS (e.g., metal in head, history of seizure, known brain lesion) 12. Treatment with an investigational drug or other intervention within the study period 13. The patient experiences a relapse between baseline and screening, defined as a moderate depression (MADRS \>=20) and a 25% increase from screening to baseline 14. Require a benzodiazepine with a dose \> lorazepam 2 mg/day or equivalent or any anticonvulsant (with the exception of Gabapentin, pregabalin, and lamotrigine).
Conditions Dyspepsia, Gastroparesis, Anxiety, Depre...
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

This study examines whether participating in poetry workshops can improve emotional well-being among patients with chronic digestive symptoms. Many individuals with long-standing digestive conditions experience distress, anxiety, isolation, and difficulty expressing their emotions in clinical settings. These emotional challenges can negatively affect daily life, relationships, and overall health. Poetry writing offers a creative and supportive way for participants to explore their feelings, express their experiences, and build emotional resilience. It also allows individuals to focus on aspects of their identity beyond their illness. The purpose of this research is to evaluate whether poetry workshops can reduce anxiety, lessen feelings of isolation, and strengthen participants' sense of community and well being. 1\. Why is this study being done? The purpose of this research study is to offer a creative outlet for patients to explore their identity and story, build resilience, and seek hope. This study is being done because we understand that the psychological discomfort that can come upon hearing a diagnosis can lead to increased anxiety levels, negatively impacting a patient's well-being and relationships. Often healthcare practitioners may merely view a patient through the lens of their diagnosis, neglecting other aspects of their identity and humanity. Through reading various poems, crafting their own poems, and sharing their work with their peers, we hope the workshops offer a comforting opportunity for the participants to explore their identities and creativity.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Poetry — participants will have the opportunity to craft their own poem and share their art with their fellow participants. This will be facilitated by one of the research team members who will help them craft their own poem.
  • Behavioral: Poetry Manual — Participants will receive a written manual that will guide them on how to write poetry. they will receive one manual each week.

Primary Outcomes

  • Change in Anxiety and Depression Symptoms (Between baseline and 8 weeks after start of poetry sessions)
  • Change in Dyspepsia Symptoms (Assessed from Baseline to end of poetry sessions (8 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-17
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ohio State University
Principal Investigators:
  • Subhankar CHAKRABORTY, MD, Ph.D. (PRINCIPAL_INVESTIGATOR) - Ohio State University
Contact Information
Study Contact:
SUBHANKAR CHAKRABORTY, M.D., Ph.D.
614-293-6255'
Subhankar.chakraborty@osumc.edu
Subhankar Chakraborty, MD, Ph.D.
614-293-6255'
subhankar.chakraborty@osumc.edu
Ohio State University Wexner Medical Center
Interventions
  • Behavioral: Poetry — participants will have the opportunity to craft their own poem and share their art with their fellow participants. This will be facilitated by one of the research team members who will help them craft their own poem.
  • Behavioral: Poetry Manual — Participants will receive a written manual that will guide them on how to write poetry. they will receive one manual each week.
Study Locations (1 sites)
Ohio State University Wexner Medical Center, Columbus, Ohio 43210 United States
Eligibility Criteria
Inclusion Criteria: * • At least 18 years old * Ability to provide informed consent * Able to speak and understand English * Able to attend virtual poetry workshops * Willing to share at least 3 poems at the end of the study with the study team * Have access to a high-speed internet connection and smart phone or computer * Willing to participate in group activity if randomized to the facilitated workshops * At least moderate dyspepsia assessed by the Dyspepsia questionnaire (at least one of the following symptoms with moderate or worse severity- nausea, vomiting, early satiety, post prandial fullness AND * At least moderate anxiety or depression assessed by HADS questionnaire. The HADS score has 2 subscores- HADS-A for anxiety and HADS-D for depression. A score of ≥ 21 indicates moderate anxiety and will be required to be eligible for the study. Exclusion Criteria: * Unable to speak English or participate in virtual sessions * Younger than 18 years old
Conditions Cardiac Disease, Depression
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

MANCAVA sets out fundamental methodologies for characterizing human fundamental physiological system interactions at a whole-body level, particularly focusing on the interplay among cortical brain activity, autonomic function, and cerebrovascular autoregulatory mechanisms. By investigating the complex, time-varying mechanisms underlying the multisystem dynamic interactions, novel methods linking various brain areas and reflex functions to target organs and districts such as heart and circulatory system are proposed with the clinical aim linked to the emerging topic of depression. In this scenario, proper new mathematical tools will allow a significant leap from the current state of the art, paving the way towards a new understanding of leading comorbid contributors to global diseases such as cardiac and cerebrovascular morbidity in mood disorders. In turn, this will provide an integration among physiological and psychological dimensions for a more holistic view on depression. Researchers, professionals, and patients will all benefit from a comprehensive assessment of brain-mind-body interplay, leading to the new extended definition of default mode/mood network, neurovascular-evoked responses to autonomic stimuli, brain-autonomic consequences of emotional responses, and physiological substrates of depressive states.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Procedure: Major Cardiac surgery — From a clinical perspective, MANCAVA will especially target neuro-cardiovascular health and mood disorders such as depression

Primary Outcomes

  • Autoregulation index (ARI) (24 months)
  • number of patients developing depression (24 months)
  • Baroreflex sensitivity (24 months)
  • Cortical activity (24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-30
Completion: 2029-02-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: IRCCS Policlinico S. Donato
Contact Information
Study Contact:
Vlasta Bari, PhD
+390252774381
vlasta.bari@grupposandonato.it
IRCCS Policlinico San Donato
Pavandeep Singh
pavandeep.singh@grupposandonato.it
IRCCS Policlinico San Donato
Marco Ranucci, MD
IRCCS Policlinico San Donato
Interventions
  • Procedure: Major Cardiac surgery — From a clinical perspective, MANCAVA will especially target neuro-cardiovascular health and mood disorders such as depression
Study Locations (1 sites)
IRCCS Policlinico San Donato, San Donato Milanese, Milan 20097 Italy
Eligibility Criteria
Inclusion Criteria: * age older than 18 years * spontaneous sinus rhythm * signed informed consent * indication to heart surgery Exclusion Criteria: * age lower than 18 years * absence of sinus rhythm * pregnancy * impossibility of informed consent